| Cas No.: | 2095719-92-7 |
| Chemical Name: | ERK1/2 inhibitor 2 |
| Synonyms: | ASTX-029;ASTX 029;ASTX029 |
| SMILES: | ClC(C(C1=CC2=C(CN([C@H](C)C(N[C@H](CO)C3=CC(F)=CC(OC)=C3)=O)C2=O)C=C1)=N4)=CN=C4NC5CCOCC5 |
| Formula: | C29H31ClFN5O5 |
| M.Wt: | 584.04 |
| Purity: | >98% |
| Sotrage: | Powder-20°C3 years4°C2 yearsIn solvent-80°C6 months -20°C1 month |
| Publication: | 1. Munck, J., Berdini, V., Courtin, A., et al. The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models. Eur. J. Cancer 138(Suppl 2), S53 (2020) |
| Description: | ERK1/2 inhibitor 2 (Example 1) is a potent dual ERK1/2 inhibitor. ERK1/2 inhibitor 2 has anti-cancer activity. |
MSDS
| TITLE | DOWNLOAD |
| MSDS_23373_DC40360_2095719-92-7 |
|
COA
| LOT NO. | DOWNLOAD |
|
|